LifeMD offers Wegovy telehealth subscription

LifeMD is launching an industry-first telehealth subscription program for Novo Nordisk's Wegovy®, potentially saving patients up to $1,200 annually on the GLP-1 therapy. This collaboration expands LifeMD's partnership with Novo Nordisk, making the popular weight-loss drug more accessible. The program aims to streamline access to treatment and provide ongoing support for patients managing their health. This initiative represents a significant development in telehealth services for chronic condition management and pharmaceutical access.